Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TCBP

TC Biopharm (TCBP) Stock Price, News & Analysis

TC Biopharm logo

About TC Biopharm Stock (NASDAQ:TCBP)

Key Stats

Today's Range
$0.50
$0.50
50-Day Range
$0.68
$0.68
52-Week Range
$0.50
$160.00
Volume
N/A
Average Volume
177,918 shs
Market Capitalization
$205 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Receive TCBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TCBP Stock News Headlines

Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.tc pixel
TC BioPharm Holdings PLC (TCBPY)
TC Biopharm announces transition to OTC Markets from Nasdaq
See More Headlines

TCBP Stock Analysis - Frequently Asked Questions

TC Biopharm's stock reverse split on Monday, February 10th 2025.The 1-20 reverse split was announced on Wednesday, February 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

TC Biopharm (TCBP) raised $17 million in an IPO on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton served as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that TC Biopharm investors own include Johnson & Johnson (JNJ), Procter & Gamble (PG), Taiwan Semiconductor Manufacturing (TSM), ExxonMobil (XOM), International Business Machines (IBM), NextEra Energy (NEE) and Union Pacific (UNP).

Company Calendar

Today
8/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TCBP
CIK
1872812
Fax
N/A
Employees
80
Year Founded
2013

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
1.12
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$4.76 million
Price / Sales
0.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$519.58 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
410,000
Free Float
28,000
Market Cap
$205 thousand
Optionable
Not Optionable
Beta
0.01

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:TCBP) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners